This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
11 Mar 2013

Drug formulation developer Dyax announces board changes

The executive vice president chief operating officer of the company, which specialises in drug formulations for unmet medical needs, is leaving for other opportunities.

Drug formulation developer Dyax Corp has announced the departure of its executive vice president chief operating officer.


Ivana Magovcevic-Liebisch PhD JD is leaving to pursue a senior management opportunity at a multinational pharmaceutical company. The move takes effect from 29th March 2013.
President and chief executive officer of Dyax Gustav Christensen extended the company's gratitude to Ms Magovcevic-Liebisch.


"She has played an important role in building Dyax into a successful commercial company and has helped establish an internal organization that is well-equipped to advance the Company’s strategy moving forward," he added.


Dyax specialises in drug formulations in the form of novel biotherapeutics for unmet medical needs. This includes the Kalbitor business and an angioedema portfolio.
Last week, Synteract announced the formation of a new clinical trial business called SynteractHCR, following the acquisition of Harrison Clinical Research.
Extract:    

Related News